



**UNIVERSITY
OF TURKU**

This is an Accepted Manuscript version of the article published originally by Elsevier, accepted for publication in the journal:

Food Bioscience

This version may differ from the original in pagination and typographic details. When using please cite the original.

AUTHOR(S)	Chen, K., Wei, X., Zhang, J., Gudmundsson, H. G. Haraldsson, G. G., Sheng, Q., Zhang, Y., & Yang, B.
TITLE	Effect of feed supplementation with docosahexaenoic acid in regio- and enantiopure triacylglycerols on gut metabolome and microbiota in rats
YEAR	2024
DOI	10.1016/j.fbio.2024.103875
CITATION	Chen, K., Wei, X., Zhang, J., Gudmundsson, H. G., Haraldsson, G. G., Sheng, Q., Zhang, Y., & Yang, B. (2024). Effect of feed supplementation with docosahexaenoic acid in regio- and enantiopure triacylglycerols on gut metabolome and microbiota in rats. <i>Food Bioscience</i> , 59, 103875. https://doi.org/10.1016/j.fbio.2024.103875
VERSION	Accepted Manuscript
LICENSE	© This version has been published under A Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license; https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en

1 Effect of feed supplementation with docosahexaenoic acid in regio- and enantiopure
2 triacylglycerols on gut metabolome and microbiota in rats

3 Kang Chen[†], Xuetao Wei[‡], Zhang Jian[§], Haraldur G. Gudmundsson[#], Gudmundur G. Haraldsson[#],
4 Qinghai Sheng[&], Yumei Zhang^{§*}, Baoru Yang^{†*}

5

6 [†]Food Sciences, Department of Life Technologies, University of Turku, FI-20014 Turun yliopisto,
7 Finland

8 [‡]Beijing Key Laboratory of Toxicological Research and Risk Assessment for Food Safety,
9 Department of Toxicology, School of Public Health, Beijing University, Beijing 100191, China

10 [§]Department of Nutrition and Food Hygiene, School of Public Health, Beijing University, Beijing
11 100191, China

12 [#] Science Institute, University of Iceland, IS-107 Reykjavik, Iceland

13 [&]College of Food Science and Technology, Hebei Agricultural University, Baoding 071001, China

14 * Author for Correspondence:

15 Professor Baoru Yang,

16 baoru.yang@utu.fi; Tel: +358 452737988

17 *Co-correspondence:

18 Professor Yumei Zhang

19 Email: zhangyumei@bjmu.edu.cn; Tel: +8613426134251

20

21

22

23

24 **Abstract**

25 Docosahexaenoic acid [22:6(n-3), DHA] plays an important role in human physiology including
26 gut health. This research aimed to investigate the impact of positional distribution of DHA in
27 dietary triacylglycerols (TAG) on gut metabolomic profile and microbiota. In the 4-week feeding
28 trial, the Sprague-Dawley rats were fed on an n-3 deficient feed supplemented with TAG
29 containing DHA at the *sn*-1, 2, or 3 position and palmitic acid at the remaining positions. Three
30 groups receiving standard n-3 adequate feed, n-3 deficient feed, or n-3 deficient feed supplemented
31 with tripalmitin were included as controls. The gut metabolome was studied using LC–MS-based
32 non-targeted metabolomics, and microbiota profiles were investigated by 16S rRNA sequencing.
33 Compared to the n-3 adequate diet, four-week feeding on the n-3 deficient diet affected the fecal
34 pyrimidine metabolism, steroid biosynthesis, and arginine and proline metabolism. Feeding with
35 DHA-containing TAGs, especially TAG with DHA at *sn*-3 position, increased the level of N5-
36 Carboxy aminoimidazole ribonucleotide related to purine biosynthesis and dimethylbenzimidazole
37 involved in vitamin B2 biosynthesis. N-3 deficient diet lowered the abundance of the genus
38 *Alistipes* and the species *Bacteroides massiliensis* in the gut microbiota. Compared to the n-3
39 deficient groups, feeding with DHA-containing TAGs decreased the abundance of species
40 *Prevotella* sp. CAG: 1031, and feeding with *sn*-2 DHA resulted in an increase in the abundance
41 of *Bacteroides fragilis* and a decrease in the abundance of *Faecalibacterium* sp. CAP 74. This is
42 the first study showing that dietary DHA from different positions of TAG may affect gut
43 metabolites and microbiota differently.

44 **Keywords**

45 Docosahexaenoic acid, N-3 deficiency, Positional isomer, Triacylglycerols, Gut microbiota, Gut
46 metabolome

47 1. Introduction

48 Triacylglycerols (TAGs) are the main source of fatty acids (FAs) in human diet, including
49 long-chain (n-3) polyunsaturated FAs (n-3 PUFAs) such as docosahexaenoic acid (DHA). DHA
50 takes part in numerous biological functions such as retinal and neural development and prevention
51 of cardiac and circulatory disorders (Hull, 2011; Swanson et al., 2012).

52 Structures of TAG molecules play an important role not only in the absorption but also the
53 metabolism of dietary n-3 PUFAs. In a TAG molecule, FAs are esterified to three stereospecific
54 positions on the glycerol backbone. The positions occupied by these FAs are numbered relative to
55 their stereospecific numbering (*sn*) as *sn*-1, *sn*-2, and *sn*-3. TAGs are to a large extent chiral in
56 nature (Gunstone & Harwood, 2007) and they are metabolized in the chiral physiological
57 environment (Carrière et al., 1997; Lehner & Kuksis, 1993; Yang et al., 1995, 2011). During
58 digestion, dietary TAGs are hydrolyzed by the action of lipases including gastric lipase and
59 pancreatic lipase, which are normally regio- and enantioselective. For example, gastric lipase of
60 seals has been shown not to hydrolyze long chain n-3 PUFAs at the *sn*-2 position of TAGs (Iverson
61 et al., 1992). Gastric lipases have been reported to hydrolyze FAs at *sn*-3 position faster than those
62 at *sn*-1 position (Duan, 2000). Dog pancreatic lipase has shown preference for n-3 PUFAs at the
63 *sn*-3 position of TAGs (Carrière et al., 1997). Lipoprotein lipase, which hydrolyzes TAGs from
64 chylomicron, has been reported to have positional priority towards the *sn*-1 position (Morley &
65 Kuksis, 1972). We have previously assessed the bioavailability of DHA from enantiopure
66 triacylglycerols and their regioisomeric counterparts in rats, quantitative lipid analysis showed that
67 less fecal excretion of DHA was detected in rats fed with TAGs containing DHA at the *sn*-2
68 position compared to those fed with DHA at the *sn*-1 or *sn*-3 position of TAGs (Linderborg et al.,
69 2019).

70 Gut metabolic and microbiota profiles are important for maintaining gut health. DHA
71 supplementation has been revealed to have a regulatory effect on fecal metabolic and microbiota
72 profiles and gut health (Dong et al., 2022; Zhuang et al., 2021). For example, the DHA supplement
73 in the form of algae oil has been reported to alter fecal cholesterol metabolism and purine
74 metabolism pathways and decrease the abundance of *Bacteroides* and *Prevotella_9* in HIV-
75 infected patients (R. Dong et al., 2022). A review has pointed out that DHA supplementation has
76 often accompanied a decrease in *Faecalibacterium* abundance and an increase in *Lachnospiraceae*
77 abundance (Costantini et al., 2017). Supplementation with mixture of EPA and DHA at an equal
78 ratio has been shown to ameliorate the dysfunction of the intestinal barrier and decrease the high
79 PPAR- γ level caused by ischemia and reperfusion intestinal injury in rats (Wang et al., 2012).
80 Studies in both humans and animals emphasize the capacity of omega-3 PUFAs to impact the gut-
81 brain connection by altering the composition of the gut microbiota (Costantini et al., 2017). In
82 addition, supplementation of DHA affected locomotor activity and anxiety-related behaviors of
83 rats with brain diseases (Arteaga et al., 2017; Xiao et al., 2022) and exposed to social isolation
84 stress (Oshima et al., 2017). Enhanced permeability leads to an inflammatory reaction, wherein
85 microglia and peripheral monocytes are activated to traverse the blood-brain barrier, resulting in
86 the release of inflammatory cytokines and neurotoxic molecules, subsequently initiating
87 neuroinflammation. DHA significantly enhances gut barrier integrity by modulating the growth of
88 butyrate-producing bacteria (La Rosa et al., 2018), thus indicating the link of dietary intake of
89 DHA with the brain-gut-microbiota axis. However, little is currently known about how the
90 different regio- and enantiospecific forms of TAGs containing DHA affect the fecal metabolic
91 profile, microbiota composition and locomotor activity. This gap in knowledge has been caused
92 by the challenge in the synthesis of regio- and enantiospecifically structured TAGs in quantities

93 required for *in vivo* studies. Due to the difference in digestion and absorption of enantiospecifically
94 structured TAGs containing DHA, their effect on fecal metabolic profile, microbiota composition
95 and locomotor activity might be also different.

96 The study aimed to investigate i) how n-3 PUFA adequate diet and n-3 PUFA deficient diet
97 affect fecal metabolic profile and microbiota composition; ii) how dietary TAGs possessing DHA
98 either in *sn*-1, *sn*-2 or *sn*-3 position and two palmitic acid residues in the remaining *sn*-positions,
99 [*sn*-22:6(n-3)-16:0-16:0, *sn*-16:0- 22:6(n-3)-16:0 or *sn*-16:0-16:0-22:6(n-3)], supplemented to the
100 n-3 deficient diet, would affect fecal metabolic profile and microbiota composition. To the best of
101 our knowledge, this is the first study comparing the effect of DHA from the *sn*-1, *sn*-2 or *sn*-3
102 positions of TAGs on fecal metabolic profile and microbiota composition. A group fed with n-3
103 deficient diet supplemented tripalmitin was also included to study the impact of increased dietary
104 intake of palmitic acid on gut microbiota.

105 **2. Method and Material**

106 **2.1 Synthesis of regio- and enantiopure structured triacylglycerols**

107 The study was enabled by chemoenzymatic synthesis of regio- and enantiospecific TAGs
108 containing DHA at *sn*-1, 2, or 3 position and palmitic acid in the remaining positions in quantities
109 sufficient for rat feeding and by the development of a powerful method of chiral liquid
110 chromatographic analysis (Kalpio et al., 2020; Kristinsson et al., 2014).

111 **2.2 Animals and diets**

112 The study was approved by the Ethical Committee of Peking University (Ethical approval number:
113 LA202129). Seventy-two male Sprague-Dawley rats (age 21 ± 2 days) were maintained in a
114 specific pathogen-free environment at the Animal Housing Unit of Peking University under
115 controlled temperature (23–25 °C) and a 12 h light/12 h dark cycle. Each rat was housed in one

116 cage and kept on adaptive feeding of standard AIN-93G diet containing soybean oil as a source of
117 n-3 PUFA for the purpose of adaptation. The composition of AIN-93G diet (Nuoyuan
118 biotechnology Co., Ltd, Beijing, China) is shown in Table S1. After the 7 days of adaptation, the
119 rats were randomly divided into 6 experimental groups, 12 rats in each group, fed with different
120 diet for 4 weeks. Five groups were fed with n-3 deficient AIN-93G feed containing peanut oil (n-
121 3 deficient oil) as the only source of FAs, while the sixth group was on the standard AIN-93G
122 containing soybean oil (n-3 adequate oil, containing precursor n-3 fatty acids but no DHA) as a
123 source of FAs (Con group). The FAs compositions of peanut oil and soybean oil are listed in Table
124 S2. Among the five groups fed with the n-3 deficient feed, four groups received 2,3-dipalmitoyl-
125 1-docosahexaenoyl-*sn*-glycerol (sn1DHA group), 1,3-dipalmitoyl-2-docosahexaenoyl-*sn*-glycerol
126 (sn2DHA group), 1,2-dipalmitoyl-3-docosahexaenoyl-*sn*-glycerol (sn3DHA group), or tripalmitin
127 (Trip group) as the experimental fat at a daily dosage of 500 mg/kg body weight for four weeks,
128 while the fifth group received no fat supplementation serving as the n-3 deficient control (n3De
129 group). The TAG having *sn*-2 DHA is a regioisomer of the TAGs with DHA at *sn*-1 or *sn*-3 position,
130 whereas the latter two TAGs are two enantiomers differing only in the positioning of fatty acids
131 between the two outer positions (*sn*-1 and *sn*-3). The daily dosage of experimental fat was selected
132 based on previous studies on n-3 PUFA interventions (Ghasemifard et al., 2014; Kaur et al., 2010).
133 α -Tocopherol (100 mg/100 g) as an antioxidant was added to the experimental fats before dividing
134 the fat into individual doses. Individual doses were stored under nitrogen at -80°C . Each daily
135 dosage of experimental fat was embedded in a pellet of n-3 deficient feed. The aliquots of
136 experimental fat were melted quickly using a water bath at 40°C and pipetted between two halves
137 of feed pellets. The pellets containing the experimental fats were prepared the day before the
138 feeding, stored at dark $+4^{\circ}\text{C}$ overnight and given to the rats as the first feed in the morning. Rodent

139 chows are removed from cages during administration of TAGs. Once the experimental fat pellets
140 were consumed completely, the rats were then provided feed *ad libitum*. The n3De and Con groups
141 were provided feed *ad libitum*. The fecal samples were collected on the day 28 and stored for a
142 maximum of 4 weeks before analysis.

143 **2.3 Open field test**

144 The open field test (OFT) is a widely used behavioral assay in rodent research to assess general
145 locomotor activity and anxiety-related behaviors. At the end of the feeding period (the day before
146 sacrifice), all rats were assessed for the general locomotor and exploratory behavior in the open
147 field test (OFT). The $100 \times 100 \times 50 \text{ cm}^3$ apparatus was constructed and overlaid on an 8×8 grid.
148 During testing, the outer walls of the apparatus were covered with dark poster board to ensure rats
149 could not see beyond the apparatus. Rats were individually tested for a period of 5 min and the
150 video tracking software Anymaze (Stoelting AnyMaze Software, Wood Dale, IL, USA) was used
151 for accurate measurements of locomotion. Experimenters were not present in the room during the
152 testing. The animals were tested in a randomized manner. Performance parameters related to
153 locomotor activity were recorded and calculated including total distance traveled, center distance
154 traveled, peripheral distance traveled, time spent in the center quadrant (4×4 center grid), time
155 spent in the periphery (all areas except center quadrant), and the number of entries into each zone.
156 Zone entry was defined as the front paws and shoulders being placed into the area. The field was
157 cleaned by wiping with 70% ethanol between each testing rat.

158 **2.4 Non-targeted Fecal Metabolomics**

159 Fecal nontargeted metabolomics analysis (12 fecal samples per group) was performed, the protocol
160 was followed the previous protocol (H. Wang et al., 2022). Briefly, 300 μL of methanol (Merck
161 KGaA, Darmstadt, Hessen, Germany) containing isotopically-labeled internal standards

162 (Cambridge Isotope Laboratories, Tewksbury, MA, USA) was mixed with fecal sample (100 µg).
163 The supernatant was collected and filtered after centrifuging at $12000 \times g$ for 15 min at 4 °C. The
164 resultant extracts were analysed using a UHPLC system (Vanquish, Thermo Fisher Scientific,
165 Waltham, MA) with a UPLC BEH Amide column (1.7 µm, 2.1 mm *100 mm, Waters) coupled to
166 TripleTOF 5600 (Q-TOF, AB Sciex, Milford, MA, USA). The mobile phase consisted of 25 mM
167 NH₄OAc and 25 mM NH₄OH in water (Merck KGaA) (pH=9.75) (A) and acetonitrile (Merck
168 KGaA) (B) was carried with elution gradient as follows: 0 min, 95% B; 7 min, 65% B; 9 min, 40%
169 B; 9.1 min, 95% B; 12 min, 95% B, which was delivered at 0.5 mL/min. The injection volume was
170 3 µL. The Triple TOF mass spectrometer was used for its ability to acquire MS/MS spectra on an
171 information-dependent basis (IDA) during an LC/MS experiment. In this mode, the acquisition
172 software (Analyst TF 1.7, AB Sciex) continuously evaluates the full scan survey MS data as it
173 collects and triggers the acquisition of MS/MS spectra depending on preselected criteria. In each
174 cycle, 12 precursor ions whose intensity greater than 100 were chosen for fragmentation at
175 collision energy (CE) of 30 V (15 MS/MS events with product ion accumulation time of 50 msec
176 each). ESI source conditions were set as following: Ion source gas 1 as 60 Psi, Ion source gas 2 as
177 60 Psi, Curtain gas as 35 Psi, source temperature 650 °C, Ion Spray Voltage Floating 5000 V or –
178 4000 V in positive or negative modes, respectively. Metabolite annotation was carried out by using
179 an in-house MS2 database. MS1 accurate mass tolerance is 0.01 Da. MS2 accurate mass tolerance
180 is 0.05 Da. The normalized peak intensities of the features were used for comparison between
181 different groups. The method of data normalization adopted was total peak area normalization.

182 **2.5 Gut Microbiota Analysis**

183 The genomic DNA extraction from feces, PCR amplification, and sequencing (n = 6, each group)
184 were conducted by following the protocol described previously (X. Dong et al., 2022). Briefly, the

185 total bacterial DNA was extracted from the colonic content by using a TIANamp Stool DNA kit
186 (TIANGEN Bio-Tech Co., Ltd, Beijing, China). The V4 region of the 16S rRNA gene was
187 amplified using specific primers with the barcode (515F: GTGCCAGCMGCCGCGGTAA and
188 806R: GGACTACHVGGGTWTCTAAT). After amplification of V4 hypervariable region of the
189 bacterial 16S rRNA gene, the resulting PCR products were extracted, purified, and quantified.
190 DNA library was constructed using the TruSeq DNA Sample Prep kit (Illumina, San Diego, CA,
191 USA) and sequenced on an Illumina MiSeq platform (Illumina). Taxonomic annotation was carried
192 out by using the Silva (release 138.1). The comparison of the relative abundance of taxa among
193 different groups were performed by Student t-test. PICRUSt2 was used to perform microbial
194 metabolic function prediction from 16S rRNA results (Douglas et al., 2020).

195 **2.6 Statistical analysis**

196 One-way Analysis of Variance (ANOVA) was tested for significance between the intervention
197 groups and followed by Tukey's HSD with Bonferroni corrections ($P < 0.05$). Tamhane's T2
198 analysis was used when variances were not homogenous. A two-side hypergeometric test was used
199 as the statistical test method and Benjamini–Hochberg was used as the FDR correction method in
200 the metabolites KEGG enrichment analysis. OPLS-DA was not chosen due to permutation tests
201 were failed to validate the model thus partial least squares discriminant analysis (PLS-DA) was
202 applied in multivariate analysis using SIMCA-P+ (V12.0, Umetrics AB, UmeÅ, Sweden). The
203 PLS-DA models were validated by permutation test (R^2Y -intercept < 0.3 – 0.4 and Q^2Y -
204 intercept < 0.05) (Eriksson, 2002) and cross-validated analysis of variance (CV-ANOVA) ($P < 0.05$).
205 Linear discriminant analysis (LDA) effect size (LEfSe) was used to discriminate differentially
206 abundant bacterial taxa, bacterial taxa with LDA absolute value > 2 were considered differentially
207 abundant bacterial.

208 **3. Results**

209 **3.1 Behavioral outcomes**

210 In this study, behavioral outcomes in rats were shown in Figure 1. OFT revealed that deficiency in
211 dietary n-3 FA for 4 weeks showed a trend of decrease in center distance (Figure 1B), distance
212 percentage in center (Figure 1D), center times (Figure 1F), and center entries (Figure 1H), although
213 the difference compared with n-3 adequate group (n3De vs Con) did not reach statistical
214 significance due to the high deviation. However, sn2DHA group showed lower center distance and
215 center entries compared to the Con group but not n3De group.

216 **3.2 Effect of n-3 fatty acid deficient diet and supplementation with triacylglycerols**
217 **containing DHA at different positions on fecal metabolic profile**

218 A total of 1,627 features were found after removing the peaks representing internal standards and
219 the unidentified features. Table S3 shows the result of quantitative enrichment analysis based on
220 the metabolites representing the changed KEGG pathways between the groups. The paired
221 comparison between the groups n3De vs. Trip or n3De vs. sn2DHA did not show significant
222 difference in KEGG pathways analysis. The metabolites mapped to those pathways and the
223 statistical analysis among groups are shown in the Figure S1. Table 1 summarizes the significantly
224 changed pathways and the metabolites contributing to distinguished pathways revealed by
225 quantitative enrichment analysis in the n3De vs. Con, n3De vs. sn1DHA n3De vs. sn3DHA
226 comparisons. Selected significantly changed metabolites in those pathways are shown in boxplots
227 (Figure 2 A–T).

228 Compared to the Con group fed the diet with soybean oil, groups fed with peanut oil showed
229 significantly changed pyrimidine metabolism (mainly driven by lower level of thymidine,
230 dihydrouracil, and deoxyuridine; Figure 2A–C), steroid biosynthesis (24, 25 - dihydrolanosterol,

231 delta 8,14-sterol, 2, 3-epoxysqualene, and obtusifoliol; Figure 2D–G; farnesyl pyrophosphate;
232 Figure 2H), ascorbate and aldarate metabolism (glucaric acid; Figure 2I), arginine and proline
233 metabolism (proline and ornithine; Figure 2J and K; arginine, hydroxyglutarate semialdehyde, and
234 4-guanidinobutanoic acid; Figure 2L–N), metabolism of xenobiotics by cytochrome P450
235 (glutathione episulfonium ions; Figure 2O), N-glycan biosynthesis (dolichyl β -D-glucosyl
236 phosphate and glucosamine-1-phosphate (glucosamine-1P); Figure 2P and Q), histidine
237 metabolism (3-methylhistidine; Figure 2R), fatty acid biosynthesis (lower level of caprylic acid
238 and higher level of palmitic acid; Figure 2S and T), and fatty acid metabolism (palmitic acid;
239 Figure 2T). Compared to the n3De group, feeding TAGs containing DHA at *sn*-1 position
240 significantly affected pyrimidine metabolism (thymidine and dihydrouracil; Figure 2A and B),
241 steroid biosynthesis, beta-alanine metabolism (dihyrouracil; Figure 2B), and pantothenate and
242 CoA biosynthesis (dihyrouracil and 4-phosphopantothenate; Figure 2B and U). Feeding TAGs
243 containing DHA at *sn*-3 position significantly affected beta-alanine metabolism (dihyrouracil;
244 Figure 2B) compared to the n3De group. No significantly changed metabolism pathway was
245 observed in Con/Trip and n3DE/*sn*2DHA comparisons. In addition, higher level of 4-
246 guanidinobutanoic acid (Figure 2N) in n-3 deficient groups (the n3De and Trip groups) was
247 significantly reversed in *sn*2DHA and *sn*3DHA groups. The affected pathways between the Con
248 group and DHA containing groups were pyrimidine metabolism, steroid biosynthesis, N-glycan
249 biosynthesis, ascorbate and aldarate metabolism, arginine and proline metabolism, valine, leucine
250 and isoleucine biosynthesis, and sphingolipid metabolism (Table S3). The affected pathway
251 between the Trip group and *sn*1DHA/*sn*3DHA groups is beta-alanine metabolism (Table S3).
252 There was no difference in the level of palmitic acid among groups fed on diet with peanut oil. No
253 significant difference in DHA level was observed in feces among the groups (Figure S2).

254 Since not all metabolites were mapped to the KEGG pathway, PLS-DA analysis, a supervised
255 clustering method, was constructed to show group classification and to identify the most changed
256 metabolites that contribute to the group classification. Parameters for validating PLS-DA models
257 are shown in Figure S3. Figure 3A-L shows boxplots of selected metabolites that were significantly
258 changed by the feeding as indicated by the multivariate analyses. PLS-DA score plot and loading
259 plot (Figure S4, Model 1) generated from all groups showed a clear separation between the normal
260 feed group (the Con group) and groups fed n-3 fatty acid deficient peanut-oil-based chow (n3De,
261 Trip, sn1DHA, sn2DHA, and sn3DHA groups). The loading plot displays the correlation between
262 metabolites and groups. The metabolites in circles contribute to the group separation. Those
263 metabolites in the right circle such as thymidine, 13Z-docosenamide, and 2,3-dihydrodipicolinate
264 (Figure 2A, 3C and 3D) were significantly higher in the Con group compared to the other groups.
265 Those metabolites in the left circle with negative w^*c value (loading coefficient) such as
266 glucosamine-1P, N5-carboxy aminoimidazole ribonucleotide, and dimethylbenzimidazole (Figure
267 2Q, 3A and B) were lower in the Con group compared to the other groups fed with n-3 fatty acid
268 deficient peanut-oil-based rodent chow.

269 To exclude the impact caused by compositional differences between the soybean oil and the peanut
270 oil, as well as to acquire clear comparison among the groups fed with n-3 fatty acid deficient
271 peanut-oil-based rodent chow, PLS-DA model (Model 2) was generated after exclusion of the Con
272 group (Figure 4A–B), in which first component explaining 11.4% of the variation and second
273 component explaining 8.8% of the variation. The first component separated the n3De group and
274 Trip group from the sn1DHA, sn2DHA, and sn3DHA groups. Furthermore, the n3De group was
275 clearly clustered in the fourth quadrant. In the loading plot, metabolites located in the right circle
276 showed higher level in the n3De group such as 13Z-docosenamide, 2,3-dihydrodipicolinate,

277 phosphatidylinositol PI (16:1_18:1), phosphatidic acid PA (16:0_18:1), phosphatidylserine
278 PS(19:0_16:0), phosphatidylethanolamine PE (14:0_16:1), as well as 12-oxo-ETE (shown also in
279 Figure 3C-I) compared to DHA supplemented groups, whereas N5-carboxyaminoimidazole
280 ribonucleotide and dimethyl benzimidazole were lower in the n3De group and the Trip group
281 (shown also in Figure 3A–B) compared to DHA supplemented groups.

282 PLS-DA model 3 (Figure 4C–D) was performed by exclusion of n3De group from the model 2 to
283 find metabolites contributing to the classification of Trip, sn1DHA, sn2DHA, and sn3DHA groups,
284 in which first component explaining 11.6% of the variation and second component explaining 9.5%
285 of the variation. The metabolites PI (16:1_18:1), PA (16:0_18:1), 2-oxaloglutaric acid, 2,3-
286 dihydrodipicolinate, and phorbol 12,13-dibutanoate in the right circle were especially higher in the
287 Trip group, however, only changes of 2,3-dihydrodipicolinate and PA (16:0_18:1) (Figure 3D and
288 3F) reached significance. The metabolites such as sirohydrochlorin, lysoPE (18:0_0:0), N5-
289 carboxyaminoimidazole ribonucleotide, folate, and 5'-deoxyadenosine in the left circle were
290 especially lower in the Trip group compared to the DHA-fed groups (Figure 4D), in which only
291 N5-carboxyaminoimidazole ribonucleotide reached significance (Figure 3A).

292 A fourth PLS-DA model (Figure 4E–F) was performed by further exclusion of Trip group from
293 model 3 to find metabolites contributing to the classification among the three DHA-fed groups:
294 sn1DHA, sn2DHA, and sn3DHA. Although the permutation test and CV-ANOVA did not validate
295 the model 4 (R^2Y -intercept > 0.3–0.4; CV-ANOVA p-value > 0.05), score and loading plots still
296 can be utilized to indicate difference in metabolomics profiles among the groups. From PLS-DA
297 model (Figure 4E–F), the sn1DHA and sn3DHA groups were separated from each other by the
298 first component and sn2DHA group was slightly separated from sn1DHA and sn3DHA groups by
299 the second component. 2,3-Dihydrodipicolinate, deoxycholic acid (Figure 3D and K), and 4-

300 phosphopantothenate (Figure 2U) were lower whereas dimethylbenzimidazole and 7-methylric
301 acid (Figure 3B and 3L) were higher in the sn3DHA group compared to other DHA-fed groups.
302 The content of scopolamine was higher in the sn2DHA group than in the sn1DHA and sn3DHA
303 groups (Figure 3J).

304 **3.3 Effect of dietary n-3 fatty acids deficiency and triacylglycerols containing DHA at** 305 **different position on fecal microbiota**

306 To address the role of n-3 FA-deficiency diet and TAGs containing DHA at different position on
307 the gut microbial community, fecal gut microbiota taxa were identified using 16s rRNA sequencing.
308 The richness and diversity of gut microbial composition were shown in Figure 5A-D. No
309 significant difference was observed among the groups in gut microbial diversity measured as
310 Shannon index, Simpson, ACE, and Chao1. The n-3 adequate Con group showed a non-
311 significantly lower ratio of Firmicutes to Bacteroidetes compared to other groups (Figure 5E).
312 Fecal microbial composition heatmap and fecal microbial composition at phylum, class, family,
313 and genus level were shown in Figure 5F-J. To determine whether any taxa at different taxonomic
314 levels were enriched or depleted by n-3 deficiency diet and to detect potentially different impact
315 by dietary supplementation with TAGs containing DHA at different position, the linear
316 discriminant analysis (LDA) effect size (LEfSe) was calculated to pinpoint the main different
317 features at all taxa (Figure 6).

318 Genera *Methanosarcina*, *Virgibacillus*, *Robinsonella*, *Gemmiger* and species *Ruminococcus*
319 *bromii* were enriched in the n3De group compared to the Con group, whereas the genera
320 *Chryseobacterium*, *Pseudomonas*, *Pyramidobacter*, *Alistips* and species *Parabacteroides distasonis*
321 and *Bacteroides massiliensis* were depleted in the n3De group compared to the Con group (Figure
322 6). The number of significantly changed taxa was less in the Trip/n3De and n3De/sn1DHA

323 comparisons than in the comparison between n3De/sn2DHA as well as n3De/sn3DHA, indicating
324 that the n3De, Trip, and sn1DHA groups shared similar gut microbiota taxa profile. This finding
325 was also verified by the heatmap (Figure 5F) showing that the gut microbiota profile of n3De, Trip,
326 and sn1DHA were clustered together by Ward clustering method. The abundance of species
327 *Prevotella* sp. CAG: 1031 was decreased in all the three DHA groups compared to the n3De group.
328 Only the groups fed TAGs containing DHA at *sn*-2 and *sn*-3 positions showed lower abundance of
329 the genus *Ruminococcus* and species *Ruminococcus flavefaciens* compared to the n3De group.
330 The sn2DHA group showed higher abundance of genus *Bacteroides* and species *Bacteroides*
331 *fragilis* as well as lower abundance of genus *faecalibacterium* and species *faecalibacterium* sp.
332 CAP 74 compared to the n3De group. LEfSe analyses in other comparisons were shown in Figure
333 S5, the relative abundance of genus *Dorea* was higher in the Trip group compared to the sn1DHA,
334 sn2DHA, and sn3DHA groups. And there were no differentiated gut microbiota taxa found in
335 sn2DHA/sn3DHA comparison, suggesting similar gut microbiota taxa profile.

336 Function prediction of the gut microbiota revealed by PICRUST2 showed comparisons of relative
337 abundance levels of the KEGG pathway (Figure 7 and Figure S6). Biosynthesis of secondary
338 metabolites, glycerolipid metabolism, and carbapenem biosynthesis were significantly different in
339 Con/n3De comparison (Figure 7A). Feeding tripalmitin also affected gut microbiota metabolic
340 pathways. For example, biosynthesis of secondary metabolites, phosphotransferase system, and
341 pentose phosphate pathway were changed in the Trip group compared to the n3De group (Figure
342 7B). Compared to the n3De group, sn2DHA and sn3DHA showed different changes in KEGG
343 pathway (Figure 7C-D). In sn2DHA group, the pathways in starch and sucrose metabolism and
344 histidine metabolism was altered, whereas the sn3DHA group showed affected phosphotransferase

345 system, pentose phosphate pathway, and protein export. No changed pathway was detected in
346 sn1DHA/n3De comparison.

347 **3.4 Correlation between gut metabolites**

348 Correlation analysis was made between gut microbiota and metabolites. However, no correlation
349 ($r < -0.5$ or $r > 0.5$) was found between gut bacterial species and gut metabolites and between gut
350 metabolites and the predicted functions. Among gut microbiota only positive correlations were
351 found at species level within *Bacteroides* genus (Table S4). Certain selected correlation plots
352 between gut metabolites are shown in Figure 8. Palmitic acid was found to be positively correlated
353 with certain fatty acids (stearidonic acid, heptadecanoic acid, and heptanoic acid) (Figure 8A-C)
354 and negatively correlated lysoPI (16:1_0:0) and PI (18:1_18:1) (Figure 8D-E). α -Linolenic acid
355 was correlated with inositol-P-ceramide C (C26), diacylglycerol (16:1_16:1_0:0), and
356 diaminopimelic acid (Figure 8F-H). Dolichyl β -D-glucosyl phosphate was positively correlated
357 with glucosamine-1P (Figure 8I).

358 **4. Discussion**

359 The present study was conducted to investigate the impact of a four-week feeding with n-3 FA
360 deficient diet in the form of peanut-oil-based rodent chow and dietary supplementation of TAGs
361 possessing DHA either in *sn*-1, *sn*-2 or *sn*-3 position and two palmitic acid residues in the
362 remaining *sn*-positions on fecal metabolites and gut microbiota in rats.

363 Fecal content of DHA and palmitic acid is of interest since previous research has shown positive
364 impact of dietary DHA (Costantini et al., 2017), whereas dietary intake of *sn*-1/*sn*-3 palmitic acid
365 may increase the formation of calcium soap reducing the fat absorption and having negative impact
366 on gut microbiota (Wang et al., 2021). Dietary intake of saturated fatty acids was shown to reduce
367 the diversity of gut microbiota in humans (Schoeler et al., 2023). In this study, no significant

368 difference in fecal DHA level was observed among the groups. Previously in a 5-day intervention
369 feeding, fecal DHA level was slightly lower in the group fed with TAG containing DHA at *sn*-2
370 position compared to the groups fed with DHA at *sn*-1/3 positions (Linderborg et al., 2019).
371 Despite additional intake of palmitic acid in the Trip and DHA-fed groups, there are no significant
372 difference in fecal content of palmitic acid among the groups. These could have partially been
373 ascribed to the low efficiency of methanol overall for extracting lipids.

374 Quantitative pathway enrichment analysis was performed. We found metabolites thymidine,
375 dihydrouracil, and deoxyuridine involved in the pyrimidine metabolism pathway were higher in
376 the n-3 adequate Con group compared to all other groups. Disorders of brain pyrimidine
377 metabolism have been extensively reviewed to be related to neurological diseases such as sleep
378 disorders and Parkinson's disease, fecal pyrimidine metabolism might affect brain pyrimidine
379 metabolism through gut-brain axis (Vincenzetti et al., 2016). Recently fecal pyrimidine
380 metabolism has also been reported to be associated with brain function. Feeding dietary prebiotics
381 to stressed mice with sleep disorder has increased fecal pyrimidine nucleotides and improved sleep
382 disorder (Thompson et al., 2020). However, contrary results have shown a positive association
383 between metabolites involved in fecal pyrimidine metabolism (such as thymidine) and aberrant
384 brain connectivity in patients with irritable bowel syndrome (Osadchiy et al., 2020). In this study,
385 feeding TAGs containing DHA at *sn*-1 position regulated pyrimidine metabolism by mainly
386 increasing thymidine and dihydrouracil and feeding TAG containing DHA at *sn*-3 position also
387 reversed dihydrouracil level to the normal level, indicating a possible improved brain function,
388 although there were no beneficial changes in OFT. Although the mechanisms for how fecal
389 metabolites affect complex brain functions remain unknown, these data strongly support the
390 relationships between fecal pyrimidine metabolism, brain function, and n-3 FA-deficient status.

391 4-Guanidinobutanoic acid and arginine are involved in arginine and proline metabolism. Increased
392 4-guanidinobutanoic acid in serum could promote the production of ROS and indicated impaired
393 nerve system (Zhao et al., 2022). 4-Guanidinobutanoic acid level was increased in the n3De and
394 Trip groups compared to the Con group, feeding TAGs containing DHA decreased its level. The
395 n3De and Trip groups did not show altered arginine level compared to the Con groups and feeding
396 TAGs containing DHA increased the arginine level compared to n3De group. These results
397 potentially indicated an improved arginine and proline metabolism by supplementation of TAGs
398 containing DHA. Arginine plays an essential role not only in amino acid metabolism and the
399 growth hormones release, it is also the precursor for the nitric oxide (NO) which is produced by
400 the NO synthase, and gut microbiota has been reported to be capable of producing NO (Piva et al.,
401 2002; Vermeiren et al., 2009). Increased fecal arginine level in the groups fed with TAGs
402 containing DHA could possibly affect the NO level and immune system in the rats.

403 Multivariate analysis also revealed metabolites that contribute to the different metabolic profile in
404 groups. Glucosamine-1P is an important intermediate in formation of peptidoglycans as
405 components of bacteria cell wall (Ruscitto & Sharma, 2018). Increased of glucosamine-1P
406 indicated that n-3 FA deficiency diet affected gut microbiota activity in rats. N5-carboxy
407 aminoimidazole ribonucleotide which plays a center role in *de novo* purine biosynthesis in
408 microbes was increased in the n-3 deficient (n3De) group compared to the Con group. Feeding
409 tripalmitin to rats on top of n-3 FA deficient diet further increased its level. Moreover, feeding
410 TAG containing DHA also increased its level compared to the Trip group with sn3DHA group
411 showing the highest level of N5-carboxy aminoimidazole ribonucleotide followed by sn2DHA
412 group and then sn1DHA group. These results possibly indicated different dietary DHA-containing
413 TAGs affected purine metabolism differently especially those TAGs containing DHA at *sn*-2 and

414 *sn*-3 positions. Genes involved in vitamin B12 production has been identified in gut bacterial
415 genomes (Balabanova et al., 2021). In a bacteria culturing study, the supplementation of medium
416 with dimethylbenzimidazole, a lower ligand in the α -position of vitamin B12, has increased
417 vitamin B12 productivity of bacteria (Marwaha et al., 1983). In this study, feeding TAG containing
418 DHA especially at *sn*-3 position largely increased dimethylbenzimidazole level compared to other
419 DHA-fed groups, indicating a possibly more active vitamin B12 metabolism in these groups.

420 In gut bacteria, the level of 2,3-dihydrodipicolinate mainly depends on two major enzymes:
421 dihydrodipicolinate reductase and dihydrodipicolinate synthase. Both enzymes are involved in
422 lysine biosynthesis, in which dihydrodipicolinate synthase catalyzes the first step in the pathway
423 for the biosynthesis of lysine (Karsten et al., 2018). In a *Akkermansia muciniphila* culturing study,
424 mucin supplement-induced glycolysis metabolites production, which downregulated the
425 expression of dihydrodipicolinate reductase and thereby affect the 2,3-dihydrodipicolinate level
426 (Liu et al., 2021). 2,3-Dihydrodipicolinate was higher in the Con group compared to the n3De
427 group. Feeding TAGs further lowered this level, among which the sn3DHA group showed the
428 lowest level followed by the sn2DHA group and then the sn1DHA and Trip groups. These results
429 suggested n-3 FA-deficient peanut-oil-based diet and feeding fatty acids (in this case, DHA and
430 palmitic acid) in different positions of TAGs possibly affected lysine metabolism and mucin
431 degradation in gut differently.

432

433 12-Oxo-ETE has been reported to be related to the inflammation formation that occurs at sites
434 where its level increases to abnormal amounts such as in human rheumatoid arthritis, inflammatory
435 bowel disease etc. (Porro et al., 2014). Feeding TAGs containing DHA lowered the 12-oxo-ETE
436 level. Scopolamine is a nonselective muscarinic antagonist that has shown relatively rapid

437 antidepressant effects, although to date the findings are available from only limited clinical studies.
438 Scopolamine reportedly has downstream signaling effects thought to be linked to neuroplasticity
439 within glutamatergic synapses and consequent antidepressant action (Drevets et al., 2020). In this
440 study, scopolamine was higher in the sn2DHA group compared to other groups, whereas no
441 difference was found between Con and n3De groups. The Sn2DHA group showed highest level of
442 deoxycholic acid, indicating altered bile acid reabsorption or production from cholesterol (Yu et
443 al., 2021).

444 In this study, difference in gut microbiota was observed between rats fed with n-3 FA-deficient
445 diet in the form of peanut-oil-based rodent chow and n-3 FA-adequate diet in the form of soybean-
446 oil-based rodent chow, although gut microbial diversity and Firmicutes/Bacteroidetes (an indicator
447 of intestinal dysbiosis) were not altered among groups. *Robinsoniella* and *Gemmiger* were
448 enriched, whereas *Pseudomonas pyramidobacter* and *Parabacteroides distasonis* were depleted in
449 the n-3 deficient n3De group compared to the n-3 adequate Con group. *Robinsonella* has been
450 reported to be positively correlated with human fatty liver disease (Raman et al., 2013) and
451 *Gemmiger* has been shown at higher level in the gut of patients with ulcerative colitis (Nishino et
452 al., 2018). *Pseudomonas pyramidobacter* has been shown to be lower in patients with chronic
453 kidney disease and colorectal cancer (Gao et al., 2015). *Parabacteroides distasonis* has been
454 reported to be lower in patients with liver cirrhosis (Qin et al., 2014). These results indicated n-3
455 FA-deficient peanut-oil-based diet might increase the risk of these diseases through modification
456 of gut microbiota. Genera *Alistipes* and species *Bacteroides massiliensis*, which have been
457 recorded at lower level in patients with mild cognitive impairment or Alzheimer's disease (Li et
458 al., 2019; Petrov et al., 2017), was depleted in the n3De group compared to the n-3 adequate Con
459 group, suggesting n-3 PUFA deficiency in the diet might affect brain function through the gut-

460 brain axis. Dietary flaxseed oil rich in α -linolenic acid, a n-3 essential fatty acid also present in
461 soybean oil, has been reported to enrich *Alistipes* in the diabetic mice (Zhu et al., 2020). However,
462 feeding TAGs containing DHA did not affect the abundance of *Alistipes*.
463 Feeding TAGs containing DHA decreased abundance of species *Prevotella* sp. CAG: 1031
464 compared to the n3De group. *Prevotella* sp. CAG: 1031 has been reported to be higher in lean
465 pigs compared to fat pigs (Zhao et al., 2022) and lower in obese mice (Si et al., 2018).
466 Metagenomics analysis showed *Prevotella* sp. CAG: 1031 has highest copies of gene 8-amino-7-
467 oxononanoate synthase [EC:2.3.1.47] (K00652) among the species in the gut of male mice, which
468 is an enzyme involved in biotin metabolism. Biotin synthesis begins by hijacking the fatty acid
469 synthetic pathway, the downregulation of biotin metabolism might affect fatty acid synthesis (Lin
470 et al., 2010). Lower abundance of the species *Prevotella* sp. CAG: 1031 induced by feeding TAGs
471 containing DHA indicated lower biotin synthesis and possible impact on fatty acid metabolism in
472 the DHA-supplemented groups.

473

474 Different doses of n-3 polyunsaturated FAs have been reported to affect gut microbial taxa in mice
475 (Zhu et al., 2021). In this study, however, DHA at different positions in TAG showed also varying
476 effect enriching or depleting gut microbiota taxa. In this study, only the groups fed with TAGs
477 containing DHA at *sn*-2 and *sn*-3 positions decreased the genus *Ruminococcus* and the species *R.*
478 *flavefaciens* compared to the n3De group. In a study exploring involvement of gut microbiota in
479 antidepressant properties of DHA, positive correlation has been found between abundance of
480 *Ruminococcus* and depressive behavior of mice (Davis et al., 2017). *R. flavefaciens* has been
481 studied in depth in depressive behavior, showing that antidepressants could reduce the abundance
482 of *R. flavefaciens*, feeding *R. flavefaciens* to depressed mice diminished antidepressants-induced

483 decrease in depressive behavior by inducing changes in cortical gene expression, up-regulating
484 genes involved in mitochondrial oxidative phosphorylation, while down-regulating genes involved
485 in neuronal plasticity (Lukić et al., 2019). The result suggested the sn2DHA and sn3DHA groups
486 might have more potential to reduce risk of brain dysfunction by inducing positive changes to gut
487 microbiota.

488 The sn2DHA group also showed higher abundance of genus *Bacteroides* and species *B. fragilis* as
489 well as lower abundance of genus *Faecalibacterium* and species *Faecalibacterium* sp. CAP 74. A
490 review summarized that a few studies also showed some common changes in the gut microbiota
491 after n-3 PUFA supplementation, in particular, a decrease in *Faecalibacterium* often associated
492 with an increase in the *Bacteroidetes* (Costantini et al., 2017). Recent studies also have shown
493 similar observations. For example, dietary DHA-ethyl ester and n-3 PUFAs (mixture of DHA and
494 EPA) increased the *Bacteroides* abundance in the gut of rats and mice, respectively (Hosomi et al.,
495 2021; Zhu et al., 2021). We previously revealed DHA at *sn-2* position in TAG has the higher
496 bioavailability compared to DHA at other positions (Linderborg et al., 2019). Higher
497 bioavailability of DHA at *sn-2* position might induce higher abundance of *B. fragilis* and lower
498 abundance of *Faecalibacterium* sp. CAP 74. Administration of *B. fragilis* protected against
499 inflammatory colitis in mice (Mazmanian et al., 2008), and it also reduced activation of pathogenic
500 T cells and increased generation or expansion of T regulatory cells in the liver of mice (Sofi et al.,
501 2021). These indicates that the sn2DHA group might have improved immunity compared to other
502 groups.

503 Palmitic acid was found to be positively correlated with stearidonic acid, heptadecanoic acid, and
504 heptanoic acid. Palmitic acid has been reported to impair paracellular permeability and cell-cell
505 junctions (Hosomi et al., 2020). Those fatty acids positively correlated with palmitic acid could be

506 from impaired gut barrier, and/or metabolism of palmitic acid by gut microbiota. High level of
507 palmitic acid might increase the palmitoylation of and activation of type II phosphatidylinositol 4-
508 kinase (PI4KII) β , which can phosphorylate phosphatidylinositols. In this study, palmitic acid
509 might promote phosphorylation of phosphatidylinositols (Qu et al., 2021), partly contributing to
510 the negative correlation between palmitic acid, lysoPI (16:1_0:0), and PI (18:1_18:1) found in this
511 study.

512 Diaminopimelic acid is a vital component of peptidoglycan, crucial for the synthesis of bacterial
513 cell walls in many pathogenic bacteria (Jiao et al., 2022). In addition, diaminopimelic acid is a
514 specific ligand of NOD1 that regulates the proinflammatory NOD1/RIP2/NF- κ B signaling
515 pathway (Jiao et al., 2022). We found that α -linolenic acid was negatively correlated with
516 diaminopimelic acid, indicating possible regulation of gut microbiota. Pro-inflammatory
517 compound dolichyl β -D-glucosyl phosphate was positively correlated with glucosamine-1P, which
518 might have been due to the fact that dolichyl β -D-glucosyl phosphate and glucosamine-1P both
519 play roles in the N-glycosylation pathway essential for glycoprotein biosynthesis.

520 **5. Conclusion**

521 The present study was conducted to determine the impact of n-3 FA-deficient diet in the form of
522 peanut-oil-based rodent chow on gut metabolic and microbiota profiles as well as the effect of
523 supplementation of TAGs possessing DHA either in *sn*-1, *sn*-2 or *sn*-3 position. Peanut-oil-based
524 rodent chow affected several fecal KEGG pathways such as pyrimidine metabolism (thymidine,
525 dihydrouracil, and deoxyuridine), steroid biosynthesis (2, 3-epoxysqualene, 24, 25 -
526 dihydrolanosterol, delta 8,14-sterrol, obtusifoliol, and farnesyl pyrophosphate), and arginine and
527 proline metabolism (4-guanidinobutanoic acid and arginine). N5-carboxy aminoimidazole
528 ribonucleotide related to purine biosynthesis and dimethylbenzimidazole involved in vitamin B2

529 biosynthesis were increased by feeding TAGs containing DHA, especially DHA at the *sn*-3
530 position. Increased fecal arginine and decreased 4-guanidinobutanoic acid levels in the groups fed
531 with TAGs containing DHA could possibly indicate the improved immune system and nerve
532 system in the rats, respectively. Changes between groups in 2,3-dihydrodipicolinate related to
533 mucin degradation and glucosamine-1P involved in formation of cell wall indicated altered by gut
534 microbiota profile, which was verified by 16s rRNA sequencing. N-3 FA-deficient diet lowered
535 the genus *Alistipes* and species *Bacteroides massiliensis*, which indicate a potential risk for mild
536 cognitive impairment or Alzheimer's disease. This change was not reversed by addition of DHA.
537 However, feeding TAGs containing DHA at either one of the three positions and palmitic acid in
538 the remaining ones decreased the abundance of species *Prevotella* sp. CAG: 1031, and feeding
539 TAGs containing DHA at the *sn*-2 position increased abundance of *Bacteroides fragilis* and
540 decreased the abundance of *Faecalibacterium* sp. CAP 74. Only the groups fed with TAGs
541 containing DHA at *sn*-2 and *sn*-3 positions showed lower abundance of the genus *Ruminococcus*
542 and the species *R. flavefaciens* compared to the n3De group. The results indicate DHA at different
543 position of TAG affected gut metabolites and microbiota differently.

544

545 **Abbreviations Used**

546 DHA, docosahexaenoic acid; FA, fatty acids; OFT, open field test; PLS-DA, partial least squares
547 discriminant analysis; TAGs, triacylglycerols.

548 **Author Contributions**

549 Kang Chen: Conceptualization, Methodology, Formal analysis, Investigation, Data curation,
550 Writing – original draft, Xuetao Wei and Jian Zhang: Methodology and Investigation (Animal
551 feeding trial). Haraldur G. Gudmundsson: Methodology and Investigation (Synthesis of Structured

552 TAGs), Writing – review & editing. Gudmundur G. Haraldsson: Methodology, Investigation,
553 Resources (Synthesis of Structured TAGs), Writing – review & editing. Qinghai Sheng: Writing –
554 review & editing. Yumei Zhang: Conceptualization, Funding acquisition, Resources. Baoru Yang:
555 Conceptualization, Investigation, Funding acquisition, Resources, Project Administration,
556 Supervision, Validation, Writing – review & editing.

557 **Declaration of competing interest**

558 The authors declare that they have no known competing financial interests or personal
559 relationships that could have appeared to influence the work reported in this paper.

560 **Data availability**

561 Data will be made available on request.

562 **Funding sources**

563 The study was supported by the Research Council of Finland (formerly the Academy of Finland)
564 in two projects (Decision numbers: 310982 & 356891) and by the Finland-China Food and Health
565 Network as a global pilot program for research and innovation funded by the Ministry of Education
566 and Culture of Finland (2021-2024). The project was also supported by the key projects of Beijing
567 Science and Technology Committee (Decision No. D171100008017002)

568

569 **References**

570 Arteaga, O., Revuelta, M., Urigüen, L., Martínez-Millán, L., Hilarío, E., & Álvarez, A. (2017).
571 Docosahexaenoic acid reduces cerebral damage and ameliorates long-term cognitive
572 impairments caused by neonatal hypoxia–ischemia in rats. *Molecular Neurobiology*, *54*(9),
573 7137–7155. <https://doi.org/10.1007/S12035-016-0221-8/FIGURES/17>

574 Balabanova, L., Averianova, L., Marchenok, M., Son, O., & Tekutyeva, L. (2021). Microbial and
575 genetic resources for cobalamin (Vitamin B12) biosynthesis: from ecosystems to industrial
576 biotechnology. *International Journal of Molecular Sciences*, 22(9), 4522.
577 <https://doi.org/10.3390/IJMS22094522>

578 Carrière, F., Rogalska, E., Cudrey, C., Ferrato, F., Laugier, R., & Verger, R. (1997). *In vivo* and
579 *in vitro* studies on the stereoselective hydrolysis of tri- and diglycerides by gastric and
580 pancreatic lipases. *Bioorganic & Medicinal Chemistry*, 5(2), 429–435.
581 [https://doi.org/10.1016/S0968-0896\(96\)00251-9](https://doi.org/10.1016/S0968-0896(96)00251-9)

582 Costantini, L., Molinari, R., Farinon, B., & Merendino, N. (2017). Impact of omega-3 fatty acids
583 on the gut microbiota. *International Journal of Molecular Sciences*, 18(12), 2645. (no page
584 number, only paper id here. I will delete this in clean version)
585 <https://doi.org/10.3390/IJMS18122645>

586 Davis, D. J., Hecht, P. M., Jasarevic, E., Beversdorf, D. Q., Will, M. J., Fritsche, K., & Gillespie,
587 C. H. (2017). Sex-specific effects of docosahexaenoic acid (DHA) on the microbiome and
588 behavior of socially-isolated mice. *Brain, Behavior, and Immunity*, 59, 38–48. (no issue
589 number) <https://doi.org/10.1016/J.BBI.2016.09.003>

590 Dong, R., Lin, H., Ding, Y., Chen, X., Shi, R., Yuan, S., Li, J., Zhu, B., Xu, X., Shen, W., Wang,
591 K., Ding, D., & He, N. (2022). Effects of docosahexanoic acid on gut microbiota and fecal
592 metabolites in HIV-Infected patients with neurocognitive impairment: A 6-month
593 randomized, double-blind, placebo-controlled trial. *Frontiers in Nutrition*, 8, 756720.
594 <https://doi.org/10.3389/FNUT.2021.756720/FULL>

595 Dong, X., Yao, S., Deng, L., Li, H., Zhang, F., Xu, J., Li, Z., Zhang, L., Jiang, J., & Wu, W.
596 (2022). Alterations in the gut microbiota and its metabolic profile of PM2.5 exposure-

597 induced thyroid dysfunction rats. *Science of the Total Environment*, 838(3), 156402.
598 <https://doi.org/10.1016/J.SCITOTENV.2022.156402>

599 Douglas, G. M., Maffei, V. J., Zaneveld, J. R., Yurgel, S. N., Brown, J. R., Taylor, C. M.,
600 Huttenhower, C., & Langille, M. G. I. (2020). PICRUSt2 for prediction of metagenome
601 functions. *Nature Biotechnology*, 38(6), 685–688. [https://doi.org/10.1038/s41587-020-](https://doi.org/10.1038/s41587-020-0548-6)
602 0548-6

603 Drevets, W. C., Bhattacharya, A., & Furey, M. L. (2020). The antidepressant efficacy of the
604 muscarinic antagonist scopolamine: Past findings and future directions. *Advances in*
605 *Pharmacology*, 89, 357–386. <https://doi.org/10.1016/BS.APHA.2020.04.002>

606 Duan, R. (2000). Enzymatic aspects of fat digestion in the gastrointestinal tract. Fat digestion and
607 absorption. *AOAC Press*.
608 [https://books.google.com/books?hl=en&lr=&id=t5FNYzGEUDsC&oi=fnd&pg=PA25&ots](https://books.google.com/books?hl=en&lr=&id=t5FNYzGEUDsC&oi=fnd&pg=PA25&ots=asTLMhwFk-&sig=N4r3KE_ppoAIC6Rixryu4CpFwyk)
609 [=asTLMhwFk-&sig=N4r3KE_ppoAIC6Rixryu4CpFwyk](https://books.google.com/books?hl=en&lr=&id=t5FNYzGEUDsC&oi=fnd&pg=PA25&ots=asTLMhwFk-&sig=N4r3KE_ppoAIC6Rixryu4CpFwyk)

610 Eriksson, I. (2002). Multi- and megavariate data analysis principles and applications. *Journal of*
611 *Chemometrics*, 16(5), 261–262. <https://doi.org/10.1002/cem.713>

612 Gao, Z., Guo, B., Gao, R., Zhu, Q., & Qin, H. (2015). Microbiota disbiosis is associated with
613 colorectal cancer. *Frontiers in Microbiology*, 6(2), 20.
614 <https://doi.org/10.3389/FMICB.2015.00020/ABSTRACT>

615 Ghasemifard, S., Turchini, G. M., & Sinclair, A. J. (2014). Omega-3 long chain fatty acid
616 “bioavailability”: A review of evidence and methodological considerations. *Progress in*
617 *Lipid Research*, 56, 92–108. <https://doi.org/10.1016/J.PLIPRES.2014.09.001>

618 Gunstone, F. D., & Harwood, J. L. (2007). Occurrence and characterisation of oils and fats. *The*
619 *Lipid Handbook with CD-ROM, Third Edition*, 37–142.

620 Hosomi, K., Kiyono, H., & Kunisawa, J. (2020). Fatty acid metabolism in the host and
621 commensal bacteria for the control of intestinal immune responses and diseases. *Gut*
622 *Microbes*, *11*(3), 276. <https://doi.org/10.1080/19490976.2019.1612662>

623 Hosomi, R., Matsudo, A., Sugimoto, K., Shimono, T., Kanda, S., Nishiyama, T., Yoshida, M., &
624 Fukunaga, K. (2021). Dietary eicosapentaenoic acid and docosahexaenoic acid ethyl esters
625 influence the gut microbiota and bacterial metabolites in rats. *Journal of Oleo Science*,
626 *70*(10), 1469–1480. <https://doi.org/10.5650/JOS.ESS21189>

627 Hull, M. A. (2011). Omega-3 polyunsaturated fatty acids. *Best Practice & Research Clinical*
628 *Gastroenterology*, *25*(4–5), 547–554. <https://doi.org/10.1016/J.BPG.2011.08.001>

629 Iverson, S. J., Sampugna, J., & Oftedal, O. T. (1992). Positional specificity of gastric hydrolysis
630 of long-chain n-3 polyunsaturated fatty acids of seal milk triglycerides. *Lipids*, *27*(11), 870–
631 878. <https://doi.org/10.1007/BF02535866>

632 Jiao, J., Liu, J., Li, Q., Zhang, G., Pan, C., Luo, F., Zhang, Q., Qi, B., Zhao, L., Yin, P., & Shang,
633 D. (2022). Gut microbiota-derived diaminopimelic acid promotes the nod1/rip2 signaling
634 pathway and plays a key role in the progression of severe acute pancreatitis. *Frontiers in*
635 *Cellular and Infection Microbiology*, *12*, 838340.
636 <https://doi.org/10.3389/FCIMB.2022.838340/BIBTEX>

637 Kalpio, M., Magnússon, J. D., Gudmundsson, H. G., Linderborg, K. M., Kallio, H., Haraldsson,
638 G. G., & Yang, B. (2020). Synthesis and enantiospecific analysis of enantiostructured
639 triacylglycerols containing n-3 polyunsaturated fatty acids. *Chemistry and Physics of Lipids*,
640 *231*(3), 104937. <https://doi.org/10.1016/j.chemphyslip.2020.104937>

641 Karsten, W. E., Nimmo, S. A., Liu, J., & Chooback, L. (2018). Identification of 2, 3-
642 dihydrodipicolinate as the product of the dihydrodipicolinate synthase reaction from

643 *Escherichia coli*. *Archives of Biochemistry and Biophysics*, 653, 50–62.
644 <https://doi.org/10.1016/J.ABB.2018.06.011>

645 Kaur, G., Begg, D. P., Barr, D., Garg, M., Cameron-Smith, D., & Sinclair, A. J. (2010). Short-
646 term docosapentaenoic acid (22 : 5n-3) supplementation increases tissue docosapentaenoic
647 acid, DHA and EPA concentrations in rats. *British Journal of Nutrition*, 103(1), 32–37.
648 <https://doi.org/10.1017/S0007114509991334>

649 Kristinsson, B., Linderborg, K. M., Kallio, H., & Haraldsson, G. G. (2014). Synthesis of
650 enantiopure structured triacylglycerols. *Tetrahedron Asymmetry*, 25(2), 125–132.
651 <https://doi.org/10.1016/j.tetasy.2013.11.015>

652 La Rosa, F., Clerici, M., Ratto, D., Occhinegro, A., Licito, A., Romeo, M., Di Iorio, C., & Rossi,
653 P. (2018). The gut-brain axis in Alzheimer’s disease and omega-3. A critical overview of
654 clinical trials. *Nutrients*, 10(9), 1–17. <https://doi.org/10.3390/nu10091267>

655 Lehner, R., & Kuksis, A. (1993). Triacylglycerol synthesis by an sn-1,2(2,3)-diacylglycerol
656 transacylase from rat intestinal microsomes. *Journal of Biological Chemistry*, 268(12),
657 8781–8786. [https://doi.org/10.1016/S0021-9258\(18\)52942-2](https://doi.org/10.1016/S0021-9258(18)52942-2)

658 Li, B., He, Y., Ma, J., Huang, P., Du, J., Cao, L., Wang, Y., Xiao, Q., Tang, H., & Chen, S.
659 (2019). Mild cognitive impairment has similar alterations as Alzheimer’s disease in gut
660 microbiota. *Alzheimer’s & Dementia*, 15(10), 1357–1366.
661 <https://doi.org/10.1016/J.JALZ.2019.07.002>

662 Lin, S., Hanson, R. E., & Cronan, J. E. (2010). Biotin synthesis begins by hijacking the fatty acid
663 synthetic pathway. *Nature Chemical Biology*, 6(9), 682–688.
664 <https://doi.org/10.1038/nchembio.420>

665 Linderborg, K. M., Kulkarni, A., Zhao, A., Zhang, J., Kallio, H., Magnusson, J. D., Haraldsson,
666 G. G., Zhang, Y., & Yang, B. (2019). Bioavailability of docosahexaenoic acid 22:6(n-3)
667 from enantiopure triacylglycerols and their regioisomeric counterpart in rats. *Food*
668 *Chemistry*, 283(1), 381–389. <https://doi.org/10.1016/j.foodchem.2018.12.130>

669 Liu, X., Zhao, F., Liu, H., Xie, Y., Zhao, D., & Li, C. (2021). Transcriptomics and metabolomics
670 reveal the adaption of *Akkermansia muciniphila* to high mucin by regulating energy
671 homeostasis. *Scientific Reports*, 11(1), 1–13. <https://doi.org/10.1038/s41598-021-88397-z>

672 Lukić, I., Getselter, D., Ziv, O., Oron, O., Reuveni, E., Koren, O., & Elliott, E. (2019).
673 Antidepressants affect gut microbiota and *Ruminococcus flavefaciens* is able to abolish their
674 effects on depressive-like behavior. *Translational Psychiatry*, 9(1), 1–16.
675 <https://doi.org/10.1038/s41398-019-0466-x>

676 Marwaha, S. S., Sethi, R. P., & Kennedy, J. F. (1983). Influence of 5,6-dimethylbenzimidazole
677 (DMB) on vitamin B12 biosynthesis by strains of propionibacterium. *Enzyme and*
678 *Microbial Technology*, 5(5), 361–364. [https://doi.org/10.1016/0141-0229\(83\)90008-X](https://doi.org/10.1016/0141-0229(83)90008-X)

679 Mazmanian, S. K., Round, J. L., & Kasper, D. L. (2008). A microbial symbiosis factor prevents
680 intestinal inflammatory disease. *Nature*, 453(7195), 620–625.
681 <https://doi.org/10.1038/nature07008>

682 Morley, N., & Kuksis, A. (1972). Positional specificity of lipoprotein lipase. *Journal of*
683 *Biological Chemistry*, 247(20), 6389–6393. [https://doi.org/10.1016/S0021-9258\(19\)44705-](https://doi.org/10.1016/S0021-9258(19)44705-4)
684 4

685 Nishino, K., Nishida, A., Inoue, R., Kawada, Y., Ohno, M., Sakai, S., Inatomi, O., Bamba, S.,
686 Sugimoto, M., Kawahara, M., Naito, Y., & Andoh, A. (2018). Analysis of endoscopic brush

687 samples identified mucosa-associated dysbiosis in inflammatory bowel disease. *Journal of*
688 *Gastroenterology*, 53(1), 95–106. <https://doi.org/10.1007/S00535-017-1384-4/FIGURES/6>

689 Osadchiy, V., Mayer, E. A., Gao, K., Labus, J. S., Naliboff, B., Tillisch, K., Chang, L., Jacobs, J.
690 P., Hsiao, E. Y., & Gupta, A. (2020). Analysis of brain networks and fecal metabolites
691 reveals brain–gut alterations in premenopausal females with irritable bowel syndrome.
692 *Translational Psychiatry*, 10(1), 1–8. <https://doi.org/10.1038/s41398-020-01071-2>

693 Oshima, Y., Watanabe, T., Endo, S., Hata, S., Watanabe, T., Osada, K., & Takenaka, A. (2017).
694 Effects of eicosapentaenoic acid and docosahexaenoic acid on anxiety-like behavior in
695 socially isolated rats. *Bioscience, Biotechnology, and Biochemistry*, 82(4), 716–723.
696 <https://doi.org/10.1080/09168451.2017.1403888>

697 Petrov, V. A., Saltykova, I. V., Zhukova, I. A., Alifirova, V. M., Zhukova, N. G., Dorofeeva, Y.
698 B., Tyakht, A. V., Kovarsky, B. A., Alekseev, D. G., Kostryukova, E. S., Mironova, Y. S.,
699 Izhboldina, O. P., Nikitina, M. A., Perevozchikova, T. V., Fait, E. A., Babenko, V. V.,
700 Vakhitova, M. T., Govorun, V. M., & Sazonov, A. E. (2017). Analysis of gut microbiota in
701 patients with Parkinson’s disease. *Bulletin of Experimental Biology and Medicine*, 162(6),
702 734–737. <https://doi.org/10.1007/S10517-017-3700-7>

703 Piva, A., Prandini, A., Fiorentini, L., Morlacchini, M., Galvano, F., & Luchansky, J. B. (2002).
704 Tributyrin and lactitol synergistically enhanced the trophic status of the intestinal mucosa
705 and reduced histamine levels in the gut of nursery pigs. *Journal of Animal Science*, 80(3),
706 670–680. <https://doi.org/10.2527/2002.803670X>

707 Porro, B., Songia, P., Squellerio, I., Tremoli, E., & Cavalca, V. (2014). Analysis, physiological
708 and clinical significance of 12-HETE: A neglected platelet-derived 12-lipoxygenase

709 product. *Journal of Chromatography B*, 964, 26–40.
710 <https://doi.org/10.1016/J.JCHROMB.2014.03.015>

711 Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., Guo, J., Le Chatelier, E., Yao, J., Wu, L.,
712 Zhou, J., Ni, S., Liu, L., Pons, N., Batto, J. M., Kennedy, S. P., Leonard, P., Yuan, C., Ding,
713 W., & Li, L. (2014). Alterations of the human gut microbiome in liver cirrhosis. *Nature*,
714 513(7516), 59–64. <https://doi.org/10.1038/nature13568>

715 Qu, M., Zhou, X., Wang, X., & Li, H. (2021). Lipid-induced s-palmitoylation as a vital regulator
716 of cell signaling and disease development. *International Journal of Biological Sciences*,
717 17(15), 4223. <https://doi.org/10.7150/IJBS.64046>

718 Raman, M., Ahmed, I., Gillevet, P. M., Probert, C. S., Ratcliffé, N. M., Smith, S., Greenwood,
719 R., Sikaroodi, M., Lam, V., Crotty, P., Bailey, J., Myers, R. P., & Rioux, K. P. (2013). Fecal
720 microbiome and volatile organic compound metabolome in obese humans with
721 nonalcoholic fatty liver disease. *Clinical Gastroenterology and Hepatology*, 11(7), 868-875.
722 <https://doi.org/10.1016/J.CGH.2013.02.015>

723 Ruscitto, A., & Sharma, A. (2018). Peptidoglycan synthesis in *Tannerella forsythia*: Scavenging
724 is the modus operandi. *Molecular Oral Microbiology*, 33(2), 125–132.
725 <https://doi.org/10.1111/OMI.12210>

726 Schoeler, M., Ellero-Simatos, S., Birkner, T., Mayneris-Perxachs, J., Olsson, L., Brolin, H.,
727 Loeber, U., Kraft, J. D., Polizzi, A., Martí-Navas, M., Puig, J., Moschetta, A., Montagner,
728 A., Gourdy, P., Heymes, C., Guillou, H., Tremaroli, V., Fernández-Real, J. M., Forslund, S.
729 K., & Caesar, R. (2023). The interplay between dietary fatty acids and gut microbiota
730 influences host metabolism and hepatic steatosis. *Nature Communications*, 14(1), 1–16.
731 <https://doi.org/10.1038/s41467-023-41074-3>

732 Si, Y. C., Miao, W. N., He, J. Y., Chen, L., Wang, Y. L., & Ding, W. J. (2018). Regulating gut
733 flora dysbiosis in obese mice by electroacupuncture. *The American Journal of Chinese*
734 *Medicine*, 46(7), 1481–1497. <https://doi.org/10.1142/S0192415X18500763>

735 Sofi, M. H., Wu, Y., Ticer, T., Schutt, S., Bastian, D., Choi, H. J., Tian, L., Mealer, C., Liu, C.,
736 Westwater, C., Armeson, K. E., Alekseyenko, A. V., & Yu, X. Z. (2021). A single strain of
737 *Bacteroides fragilis* protects gut integrity and reduces GVHD. *JCI Insight*, 6(3), e136841.
738 <https://doi.org/10.1172/JCI.INSIGHT.136841>

739 Swanson, D., Block, R., & Mousa, S. A. (2012). Omega-3 fatty acids EPA and DHA: health
740 benefits throughout life. *Advances in Nutrition*, 3(1), 1–7.
741 <https://doi.org/10.3945/AN.111.000893>

742 Thompson, R. S., Vargas, F., Dorrestein, P. C., Chichlowski, M., Berg, B. M., & Fleshner, M.
743 (2020). Dietary prebiotics alter novel microbial dependent fecal metabolites that improve
744 sleep. *Scientific Reports*, 10(1), 1–14. <https://doi.org/10.1038/s41598-020-60679-y>

745 Vermeiren, J., Van De Wiele, T., Verstraete, W., Boeckx, P., & Boon, N. (2009). Nitric oxide
746 production by the human intestinal microbiota by dissimilatory nitrate reduction to
747 Ammonium. *Journal of Biomedicine and Biotechnology*, 2009, 284718,
748 <https://doi.org/10.1155/2009/284718>

749 Vincenzetti, S., Polzonetti, V., Micozzi, D., & Pucciarelli, S. (2016). Enzymology of pyrimidine
750 metabolism and neurodegeneration. *Current Medicinal Chemistry*, 23(14), 1408–1431.
751 <https://doi.org/10.2174/0929867323666160411125803>

752 Wang, H., Chen, Z., Wang, M., Long, M., Ren, T., Chen, C., Dai, X., Yang, S., & Tan, S.
753 (2022). The effect of polyphenol extract from *rosa roxburghii* fruit on plasma metabolome

754 and gut microbiota in type 2 diabetic mice. *Foods*, *11*(12), 1747.
755 <https://doi.org/10.3390/foods11121747>

756 Wang, L., Bravo-Ruiseco, G., Happe, R., He, T., van Dijk, J. M., & Harmsen, H. J. M. (2021).
757 The effect of calcium palmitate on bacteria associated with infant gut microbiota.
758 *Microbiology Open*, *10*(3), e1187. <https://doi.org/10.1002/MBO3.1187>

759 Wang, X., Pan, L., Lu, J., Li, N., & Li, J. (2012). N-3 PUFAs attenuate ischemia/reperfusion
760 induced intestinal barrier injury by activating I-FABP-PPAR γ pathway. *Clinical Nutrition*,
761 *31*(6), 951–957. <https://doi.org/10.1016/J.CLNU.2012.03.003>

762 Xiao, M., Xiang, W., Chen, Y., Peng, N., Du, X., Lu, S., Zuo, Y., Li, B., Hu, Y., & Li, X.
763 (2022). DHA ameliorates cognitive ability, reduces amyloid deposition, and nerve fiber
764 production in Alzheimer's disease. *Frontiers in Nutrition*, *9*, 852433.
765 <https://doi.org/10.3389/FNUT.2022.852433/BIBTEX>

766 Yang, L. Y., Kuksis, A., & Myher, J. J. (1995). Biosynthesis of chylomicron triacylglycerols by
767 rats fed glyceryl or alkyl esters of menhaden oil fatty acids. *Journal of Lipid Research*,
768 *36*(5), 1046–1057. [https://doi.org/10.1016/S0022-2275\(20\)39862-X](https://doi.org/10.1016/S0022-2275(20)39862-X)

769 Yang, L. Y., Kuksis, A., & Myher, J. J. (2011). Intestinal absorption of menhaden and rapeseed
770 oils and their fatty acid methyl and ethyl esters in the rat. *Biochemistry and Cell Biology*,
771 *68*(2), 480–491. <https://doi.org/10.1139/O90-068>

772 Yu, H., Fang, C., Li, P., Wu, M., & Shen, S. (2021). The relevance of DHA with modulating of
773 host-gut microbiome signatures alterations and repairing of lipids metabolism shifts.
774 *European Journal of Pharmacology*, *895*, 173885.
775 <https://doi.org/10.1016/J.EJPHAR.2021.173885>

776 Zhao, G., Xiang, Y., Wang, X., Dai, B., Zhang, X., Ma, L., Yang, H., & Lyu, W. (2022).
777 Exploring the possible link between the gut microbiome and fat deposition in pigs.
778 *Oxidative Medicine and Cellular Longevity*, 2022, 1098892.
779 <https://doi.org/10.1155/2022/1098892>

780 Zhao, Q., Fu, Y., Zhang, F., Wang, C., Yang, X., Bai, S., Xue, Y., Shen, Q., Zhao, Q., Fu, Y.,
781 Zhang, F., Wang, C., Xue, Y., Shen, Q., Yang, X., & Bai, S. (2022). Heat-treated adzuki
782 bean protein hydrolysates reduce obesity in mice fed a high-fat diet via remodeling gut
783 microbiota and improving metabolic function. *Molecular Nutrition & Food Research*,
784 66(8), 2100907. <https://doi.org/10.1002/MNFR.202100907>

785 Zhu, L., Sha, L., Li, K., Wang, Z., Wang, T., Li, Y., Liu, P., Dong, X., Dong, Y., Zhang, X., &
786 Wang, H. (2020). Dietary flaxseed oil rich in omega-3 suppresses severity of type 2
787 diabetes mellitus via anti-inflammation and modulating gut microbiota in rats. *Lipids in*
788 *Health and Disease*, 19(1), 1–16. <https://doi.org/10.1186/S12944-019-1167-4/FIGURES/12>

789 Zhu, X., Bi, Z., Yang, C., Guo, Y., Yuan, J., Li, L., & Guo, Y. (2021). Effects of different doses
790 of omega-3 polyunsaturated fatty acids on gut microbiota and immunity. *Food & Nutrition*
791 *Research*, 65, 6263. <https://doi.org/10.29219/FNR.V65.6263>

792 Zhuang, P., Li, H., Jia, W., Shou, Q., Zhu, Y., Mao, L., Wang, W., Wu, F., Chen, X., Wan, X.,
793 Wu, Y., Liu, X., Li, Y., Zhu, F., He, L., Chen, J., Zhang, Y., & Jiao, J. (2021).
794 Eicosapentaenoic and docosahexaenoic acids attenuate hyperglycemia through the
795 microbiome-gut-organs axis in db/db mice. *Microbiome*, 9(1), 185.
796 <https://doi.org/10.1186/s40168-021-01126-6>
797
798

799

800

801

802

803 Figure 1. Behavioral outcomes in rats following dietary TAGs containing DHA at different position
804 in the open field test. (A) Total distance; (B) Center distance; (C) Periphery distance; (D) Distance
805 percentage in center; (E) Distance percentage in periphery; (F) Center time; (G) Periphery time;
806 (H) Center entries; Note: * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$

807 Figure 2. Selected significantly changed metabolites mapped to affected metabolic pathways. Bars
808 with different letter differ from one another.

809 Figure 3. Selected significantly changed metabolites from multivariate analysis of all groups. Bars
810 with different letters differ from one another.

811 Figure 4. PLS-DA score plot (A) and loading plot (B) based on identified metabolites from n3De,
812 Trip, sn1DHA, sn2DHA, and sn3DHA groups. PLS-DA score plot (C) and loading plot (D) based
813 on identified metabolites from Trip, sn1DHA, sn2DHA, and sn3DHA groups. PLS-DA score plot
814 (E) and loading plot (F) based on identified metabolites from sn1DHA, sn2DHA, and sn3DHA
815 groups.

816 Figure 5. Gut microbiota diversity indexes (A)-(D), the ratio of Firmicutes to Bacteroidetes (E),
817 heatmap of gut microbiota abundances (F), fecal microbial composition at phylum (G), class (H),
818 family (I), and genus (J) level.

819

820 Figure 6. Significantly changed gut microbes revealed by LEfSe (LDA Effect Size) in comparisons
821 of Con/n3De, Trip/n3De, n3De/sn1DHA, n3De/sn2DHA, and n3De/sn3DHA. The unit of Y axis
822 is relative intensities.

823 Figure 7. Extended error bar plot identifying significant altered KEGG pathway of gut microbiota
824 in comparisons of Con/n3De, Trip/n3De, n3De/sn2DHA, and n3De/sn3DHA. The unit of Y axis
825 is relative intensities.

826 Figure 8. Correlation plots between selected metabolites.

827

828

829

830

831

832

833

834

835

836

837

838

839

840


841

842

843


844 Figure 1

845



846

Figure 2



Supplementary

Effect of feed supplementation with docosahexaenoic acid in regio- and enantiopure triacylglycerols on gut metabolome and microbiota in rats

Kang Chen[†], Xuetao Wei[‡], Zhang Jian[§], Haraldur G. Gudmundsson[#], Gudmundur G. Haraldsson[#], Qinghai Sheng[&], Yumei Zhang^{§*}, Baoru Yang^{†*}

[†]Food Sciences, Department of Life Technologies, University of Turku, FI-20014 Turun yliopisto, Finland

[‡]Beijing Key Laboratory of Toxicological Research and Risk Assessment for Food Safety, Department of Toxicology, School of Public Health, Beijing University, Beijing 100191, China

[§]Department of Nutrition and Food Hygiene, School of Public Health, Beijing University, Beijing 100191, China

[#] Science Institute, University of Iceland, IS-107 Reykjavik, Iceland

[&]College of Food Science and Technology, Hebei Agricultural University, Baoding 071001, China

* Author for Correspondence:

Professor Baoru Yang,

baoru.yang@utu.fi; Tel: +358 452737988

*Co-correspondence:

Professor Yumei Zhang

Email: zhangyumei@bjmu.edu.cn; Tel: +8613426134251

Table S1. Composition of diet

Ingredients	Contents (g/kg)
Corn starch	397
Casein (> 85% protein)	200
Corn dextrin (90–94% tetrose)	132
Sucrose	100
Oil ¹	70
Fiber	50
Minerals	35.5
Vitamins	10
L-cystinol	3
Choline bitartrate (42% choline)	2.5
Tert-butylhydroquinone	0.014

¹ Low n-3 FA diet (modified AIN-93G diet) for the n3De, Trip, sn1DHA, sn2DHA, and sn3DHA groups contained peanut oil. Standard n-3 AIN-93G diet for the Con group contained soybean oil

Table S2 Fatty acid composition of oils used in the feed. Values are expressed as mean mass percentages of two replicates.


Fatty acid	Soybean oil	Peanut oil
16:0	10.40	9.61
18:0	4.46	3.54
18:1(n-9)	22.95	49.75
18:2(n-6)	53.30	31.29
18:3(n-3)	7.50	0.11
20:0	0.40	1.24
22:0	0.40	2.39
24:0	0.12	1.04
Others ¹	0.47	1.03

¹ This category includes 16:1(n-7), 18:1(n-7), 18:3(n-6), 20:1(n-9) and 23:0.


Table S4 Correlation analysis between gut microbiota at species level.

Correlation pairs	Correlation coefficient	P value
('Bacteroides_sp._AM16-15', 'Bacteroides_sp._CAG:98')	0.999591571	1.54356E-52
('Bacteroides_sp._AM22-3LB', 'Bacteroides_sp._CAG:98')	0.99962793	3.31526E-53
('Bacteroides_sp._AM16-15', 'Bacteroides_sp._AM22-3LB')	0.999748845	5.06544E-56
('Bacteroides_sp._AM16-15', 'Bacteroides_sp._AM25-34')	0.999754601	3.45552E-56
('Bacteroides_sp._AM25-34', 'Bacteroides_sp._CAG:98')	0.99977323	9.39371E-57
('Bacteroides_massiliensis', 'Bacteroides_sp._AM16-15')	0.999804403	8.1895E-58
('Bacteroides_massiliensis', 'Bacteroides_sp._CAG:98')	0.999831142	7.24371E-59
('Bacteroides_sp._AM22-3LB', 'Bacteroides_sp._AM25-34')	0.99984375	2.01344E-59
('Bacteroides_massiliensis', 'Bacteroides_sp._AM22-3LB')	0.999845795	1.62004E-59
('Bacteroides_massiliensis', 'Bacteroides_sp._AM25-34')	0.999892545	4.18085E-62


A Pyrimidine metabolism




B Steroid biosynthesis




C N-Glycan biosynthesis




D Ascorbate and aldarate metabolism




E beta-Alanine metabolism




F Metabolism of xenobiotics by cytochrome P450




G Histidine metabolism




H Arginine and proline metabolism




I Fatty acid degradation




J Fatty acid biosynthesis






L Valine, leucine, and isoleucine metabolism




M Glycerolipid metabolism




N Pantothenate and CoA biosynthesis




O Steroid hormone biosynthesis



P Fructose and mannose metabolism



Q Spingolipid metabolism



R Glycine, serine and threonine metabolism




Figure S1. Metabolites mapped to those pathways in Table S3 and their statistical analysis.






Figure S2. DHA level.


A Model 1



B Model 2



C Model 3



D Model 4




Figure S3. Validation of PLS-DA models by permutation test and CV-ANOVA.




Figure S4. PLS-DA score plot (A) and loading plot (B) based on identified metabolites from all groups. Those metabolites in the right circle with positive w^*c value (a value generated from combination of the X-weights, w^* , and Y-weights, c) such as thymidine, 13Z-docosenamide, and 2,3-dihydrodipicolinate were higher in the Con group compared to the other groups. Those metabolites in the left circle with negative w^*c value such as N5-carboxy aminoimidazole ribonucleotide, glucosamine-1P, and dimethylbenzimidazole were lower in the Con group compared to the other groups fed with n-3 fatty acid deficient peanut-oil-based rodent chow.




Figure S5. Significantly changed gut microbes revealed by LefSe (LDA Effect Size).




Figure S6. Extended error bar plot identifying significant altered KEGG pathway of gut microbiot

